Research Topics
Species | P CorrealeSummaryAffiliation: University of Siena Country: Italy Publications
| Collaborators
|
Detail Information
Publications
5-fluorouracil-based chemotherapy enhances the antitumor activity of a thymidylate synthase-directed polyepitopic peptide vaccinePierpaolo Correale
Siena University School of Medicine, Viale Bracci 1, 53100 Siena, Italy
J Natl Cancer Inst 97:1437-45. 2005..CONCLUSIONS: The multiepitopic TS/PP vaccine induces a tumor-specific immune response in mice and is especially potent when used in combination with 5-FU-based chemotherapy...
Combined effects of 5-fluorouracil, folinic acid and oxaliplatin on the expression of carcinoembryonic antigen in human colon cancer cells: pharmacological basis to develop an active antitumor immunochemotherapySalvatore P Prete
Department of Neuroscience, Section of Pharmacology and Medical Oncology, University of Rome, Tor Vergata, Via Montpellier, 1, 00133 Rome, Italy
J Exp Clin Cancer Res 27:5. 2008..Thus, we investigated whether FUL in combination with OXA according to 2 different schedules may influence CEA expression in human colon cancer cells in vitro...- Biweekly triple combination chemotherapy with gemcitabine, oxaliplatin, levofolinic acid and 5-fluorouracil (GOLF) is a safe and active treatment for patients with inoperable pancreatic cancerP Correale
Medical Oncology Division, Department of Human Pathology and Oncology, Siena University School of Medicine, Italy
J Chemother 20:119-25. 2008..5 and 8 months, respectively. In conclusion, the GOLF regimen appears to be a feasible treatment for patients with advanced pancreatic carcinoma that deserves to be evaluated in phase III trials... - A novel metronomic chemotherapy regimen of weekly platinum and daily oral etoposide in high-risk non-small cell lung cancer patientsP Correale
Section of Oncology, Department of Human Pathology and Oncology, Siena University School of Medicine, I 53100 Siena, Italy
Oncol Rep 16:133-40. 2006..These preliminary results indicate that our metronomic regimen is well tolerated and active, even in patients with a very poor prognosis... - Gemcitabine (GEM) plus oxaliplatin, folinic acid, and 5-fluorouracil (FOLFOX-4) in patients with advanced gastric cancerPierpaolo Correale
Section of Medical Oncology, Human Pathology and Oncology Department, Siena University School of Medicine, Viale Bracci 11, 53100, Siena, Italy
Cancer Chemother Pharmacol 56:563-8. 2005..We have therefore designed a multi-center phase II trial in order to test a novel GEM+FOLFOX-4 regimen in patients with metastatic gastric cancer... - Dendritic cell-mediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen-specific CTL responsePierpaolo Correale
Section of Oncology, Department of Human Pathology and Oncology, Siena University School of Medicine, Viale Bracci 11, 53100 Siena, Italy
J Immunol 175:820-8. 2005.... 
Chemotherapeutic drugs may be used to enhance the killing efficacy of human tumor antigen peptide-specific CTLsPierpaolo Correale
Medical Oncology Section, Department of Human Pathology and Oncology, Siena University School of Medicine, Italy
J Immunother 31:132-47. 2008..These results may have clinical implications for the design of new translational anticancer regimens aimed at combining chemotherapy and immunotherapy...- Tumour-associated antigen (TAA)-specific cytotoxic T cell (CTL) response in vitro and in a mouse model, induced by TAA-plasmids delivered by influenza virosomesP Correale
Medical Oncology Division, Medicine School, Siena University, 53100, Siena, Italy
Eur J Cancer 37:2097-103. 2001..These results provide a rationale for investigating GC90V in clinical trials of anticancer vaccine therapy... - UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancerR Petrioli
Department of Human Pathology and Oncology, Medical Oncology Section, University of Siena, Viale Bracci 11, Siena 53100, Italy
Br J Cancer 90:306-9. 2004..There were no cases of hand-foot syndrome. This alternating regimen seems to be effective and well tolerated in the first-line treatment of patients with metastatic CRC... - A novel biweekly pancreatic cancer treatment schedule with gemcitabine, 5-fluorouracil and folinic acidP Correale
Oncology Section, Department of Human Pathology and Oncology, Siena University School of Medicine, Viale Bracci 11, 53100 Siena, Italy
Br J Cancer 89:239-42. 2003..10 months (95% CI 9.64-16.56). There were seven cases of each grade III gastroenteric and haematological toxicity. The GEM plus FUFA combination appears to be well tolerated and very active in patients with pancreatic carcinoma... - A novel biweekly multidrug regimen of gemcitabine, oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) in pretreated patients with advanced colorectal carcinomaP Correale
Section of Oncology, Human Pathology and Oncology Department, University of Siena School of Medicine, Viale Bracci 11, Siena 53100, Italy
Br J Cancer 90:1710-4. 2004..The average time to progression and overall survival of the patients was, respectively, 7.26 and 22 months. Our GOLF combination is well tolerated and seems promising for the treatment of advanced colorectal cancer... - Gemcitabine (GEM), 5-fluorouracil (5-FU) and folinic acid (FA) in patients with different gastroenteric malignanciesP Correale
Oncology Section, Department of Human Pathology and Oncology, Siena University School of Medicine, Siena, Italy
J Chemother 16:206-10. 2004..We therefore believe that an improved version would merit further investigation in larger scale trials... - Gemcitabine increases systemic 5-fluorouracil exposure in advanced cancer patientsP Correale
Section of Oncology, Department of Human Pathology and Oncology, Siena University School of Medicine, Viale Bracci 11, 53100 Siena, Italy
Eur J Cancer 39:1547-51. 2003..Our finding may be useful in designing future studies of the combination in order to reduce the occurrence of side-effects and to maximise the antitumour activity... - Oral metronomic chemo-hormonal-therapy of metastatic breast cancer with cyclophosphamide and megestrol acetateA Licchetta
Section of Medical Oncology, Department Giorgio Segre of Pharmacology, Siena University School of Medicine, Italy
J Chemother 22:201-4. 2010..0%, disease control rate 41.3%, mean time to tumor progression 7.4 months (CI 95%, 3.8-10.88, range 1-48 months) and mean overall survival 13.4 months (CI 95%, 7.24-17.18, range 1-53 months). The mCM regimen was active and well tolerated... - Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer Pierpaolo Correale
Section of Medical Oncology, Department of Human Pathology and Oncology, Siena University School of Medicine, Viale Bracci 11, 53100 Siena, Italy
J Clin Oncol 23:8950-8. 2005..CONCLUSION: The results show that our regimen has strong immunologic and antitumor activity in colorectal cancer patients and deserves to be investigated in phase III trials... - Recruitment of dendritic cells and enhanced antigen-specific immune reactivity in cancer patients treated with hr-GM-CSF (Molgramostim) and hr-IL-2. results from a phase Ib clinical trialP Correale
Division of Medical Oncology, University of Siena, Viale Bracci 11, 53100, Siena, Italy
Eur J Cancer 37:892-902. 2001..Its biological activity may support tumour associated antigen (TAA)-specific anticancer immunotherapy by increasing antigen presenting cell (APC) activity and T cell immune competence in vivo... - Occurrence of autoimmunity in a long-term survivor with metastatic colon carcinoma treated with a new chemo-immunotherapy regimenP Correale
Section of Medical Oncology, Department of Clinical Medicine and Immunological Sciences, Siena University School of Medicine, Siena, Italy
J Chemother 20:278-81. 2008..In this manuscript we describe a clinical case concerning a patient with metastatic colon carcinoma who responded to the GOLFIG regimen, showed symptoms of autoimmunity [Discoid Lupus Erythematosus (DLE)] and had a very long survival... - Chemo-hormone therapy of non-well-differentiated endocrine tumours from different anatomic sites with cisplatinum, etoposide and slow release lanreotide formulationP Correale
Medical Oncology, Department of Human Pathology and Oncology, Siena University School of Medicine, Viale Bracci 11, 53100, Siena, Italy
Br J Cancer 96:1343-7. 2007..The average time to progression and to survival were 9 and 24 months respectively. These results suggest that this chemo-hormone therapy regimen is well tolerated and active in patients with non-well differentiated endocrine tumours... - Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapyPierpaolo Correale
Department Giorgio Segre of Pharmacology, Siena University School of Medicine, Italy
J Immunother 33:435-41. 2010..1 mo vs. 9.9 mo, P=0.01). Our results suggest that a higher FoxP3+ T-lymphocyte tumor infiltration score is a favorable prognostic factor in colon cancer patients undergoing chemo or chemoimmunotherapy... - Cetuximab ± chemotherapy enhances dendritic cell-mediated phagocytosis of colon cancer cells and ignites a highly efficient colon cancer antigen-specific cytotoxic T-cell response in vitroP Correale
Medical Oncology Unit, Department of Oncology, Siena University Hospital, Istituto Toscano Tumori, Siena, Italy
Int J Cancer 130:1577-89. 2012..On the basis of our data, we suggest a possible involvement of CTL-dependent immunity in cetuximab anti-cancer effects... - Urinary calcium excretion in the monitoring of bone metastases from prostatic carcinomaG Francini
Medical Oncology Division, Institute of Internal Medicine, University of Siena, Siena, Italy
Cancer 92:1468-74. 2001.... - Immunity feedback and clinical outcome in colon cancer patients undergoing chemoimmunotherapy with gemcitabine + FOLFOX followed by subcutaneous granulocyte macrophage colony-stimulating factor and aldesleukin (GOLFIG-1 Trial)Pierpaolo Correale
Section of Medical Oncology, Department Giorgio Segre of Pharmacology, Rheumatology Unit, Siena University School of Medicine, Siena, Italy
Clin Cancer Res 14:4192-9. 2008..We have thus investigated the immunobiological feedback to the treatment and its possible correlation with the clinical outcome of these patients... - Anti-angiogenetic effects of immune-reconstituted influenza virosomes assembled with parathyroid hormone-related protein derived peptide vaccinePierpaolo Correale
Department G Segre of Pharmacology, Medical Oncology Section, Department of Human Pathology and Oncology, University of Siena, Viale Bracci 11, 53100 Siena, Italy
Cancer Lett 263:291-301. 2008..01 amino acid binding motifs. This peptide is able to generate a human PTH-rP specific CTL response with anti-tumor activity in vitro and in mice... - Immunological characterization of respiratory syncytial virus N protein epitopes recognized by human cytotoxic T lymphocytesChiara Terrosi
Microbiology Section, Department of Molecular Biology, University of Siena, Siena, Italy
Viral Immunol 20:399-406. 2007..N-RSV1 and N-RSV3 peptides elicited the strongest cytolytic activity against RSV-infected cells and they could be useful epitopes for the analysis of CTL responses to RSV and for understanding immune-induced disease pathogenesis... - Weekly epirubicin in patients with hormone-resistant prostate cancerR Petrioli
Medical Oncology Division, Institute of Internal Medicine, University of Siena, Siena, Italy
Br J Cancer 87:720-5. 2002..Weekly epirubicin chemotherapy can lead to a rapid and lasting palliative result in patients with metastatic HRPC, and have a positive effect on the quality of life and survival... - In vivo study of the GC90/IRIV vaccine for immune response and autoimmunity into a novel humanised transgenic mouseA Scardino
INSERM U 487, IGR, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
Br J Cancer 89:199-205. 2003..The immune response capacity and the absence of any sign of toxicity and/or autoimmunity in vivo suggest the GC90/IRIV vaccine as a valid tool for active specific immunotherapy of human cancers and metastases overexpressing PTH-rP... - Comparative study of the immune response in mice immunized with four live attenuated strains of mumps virus by intranasal or intramuscular routeM G Cusi
Department of Molecular Biology, University of Siena, Italy
Arch Virol 146:1241-8. 2001..Thus, the intranasal immunization could be considered a possible alternative and efficient route of vaccination against mumps... - Immune-reconstituted influenza virosome containing CD40L gene enhances the immunological and protective activity of a carcinoembryonic antigen anticancer vaccineMaria Grazia Cusi
Virology Section, Department of Molecular Biology, Siena University School of Medicine, Italy
J Immunol 174:7210-6. 2005.... - Folinic acid, 5-fluorouracil and mitomycin C in metastatic breast cancer patients previously treated with at least two chemotherapy regimensGuido Francini
Institute of Internal Medicine, Medical Oncology Division, University of Siena, Policlinico Le Scotte, Viale Bracci 11, 53100 Siena, Italy
Cancer Chemother Pharmacol 50:271-6. 2002..To assess the activity and safety of combined folinic acid (FA), 5-fluorouracil (5-FU) and mitomycin C (MMC) in metastatic breast cancer patients previously treated with at least two chemotherapy regimens... - High-affinity HLA-A(*)02.01 peptides from parathyroid hormone-related protein generate in vitro and in vivo antitumor CTL response without autoimmune side effectsGuido Francini
Division of Medical Oncology, Institut National de la Santé et de la Recherche Médicale Unité d Immunité Cellulaire Antivirale, Institut Pasteur, Paris, France
J Immunol 169:4840-9. 2002..In this study we describe two immunogenic and toxic-free PTH-rP peptides as valid candidates for the design of peptide-based vaccination strategies against prostate cancer and bone metastases from the most common epithelial malignancies... - Age related changes in T cell mediated immune response and effector memory to Respiratory Syncytial Virus (RSV) in healthy subjectsMaria Grazia Cusi
Department of Molecular Biology, Microbiology Section, University School of Medicine, V, le Bracci, 1, 53100 Siena, Italy
Immun Ageing 7:14. 2010..Our finding also lays the basis for new therapeutic perspectives that could limit or prevent severe RSV infection in elderly... - Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC)Pierpaolo Correale
Translational Immuno Oncology Unit, Medical Oncology Section, Department G Segre of Pharmacology, Siena University School of Medicine, Viale Bracci 11, 53100 Siena, Italy
Eur J Cancer 46:1703-11. 2010..The results of our study suggest that chemotherapy may enhance cetuximab-mediated immuno-targeting and ADCC thus providing the rationale to design novel immuno-biochemotherapy regimens... - Efficient delivery of DNA to dendritic cells mediated by influenza virosomesMaria Grazia Cusi
Department of Molecular Biology, Microbiology Section, University of Siena, Via Laterina 8, 53100 Siena, Italy
Vaccine 22:735-9. 2004..These findings suggest that the virosome is an efficient delivery system for testing infectious, as well as anti-cancer, DNA-based vaccine research... - Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab and has strong antitumor activity in advanced non-small-cell-lung cancer patientsPierpaolo Correale
Translational Immuno Oncology Unit, Medical Oncology Section, Department G Segre of Pharmacology, Siena University School of Medicine, Siena, Italy
Cancer Biol Ther 9:685-93. 2010..We also evaluated the antitumor activity of this combination... - Analysis of biochemical bone markers as prognostic factors for survival in patients with hormone-resistant prostate cancer and bone metastasesRoberto Petrioli
Department of Human Pathology and Oncology, University of Siena, Siena, Italy
Urology 63:321-6. 2004.... - Influenza virosomes are an efficient delivery system for respiratory syncytial virus-F antigen inducing humoral and cell-mediated immunityM G Cusi
Department of Molecular Biology, University of Siena, Via Laterina, 8 53100, Siena, Italy
Vaccine 20:3436-42. 2002..These results show that i.n. immunization of BALB/c mice with RSV-F/IRIV in combination with HLT can be considered a promising approach for the development of an efficacious human vaccine... - Weekly low-dose docetaxel in advanced non-small cell lung cancer previously treated with two chemotherapy regimensRoberto Petrioli
Medical Oncology Division, Institute of Internal Medicine, University of Siena, Policlinico Le Scotte, Viale Bracci 11, 53100, Siena, Italy
Lung Cancer 39:85-9. 2003..CONCLUSION: The results of this study suggest that weekly low-dose docetaxel is effective, well tolerated and maintains a relatively good quality of life in patients with advanced NSCLC previously exposed to two chemotherapy regimens... - Weekly low-dose docetaxel in advanced hormone-resistant prostate cancer patients previously exposed to chemotherapyRoberto Petrioli
Medical Oncology Division, Institute of Internal Medicine, University of Siena, Siena, Italy
Oncology 64:300-5. 2003..CONCLUSIONS: Weekly low-dose docetaxel is an effective and well-tolerated treatment for patients with hormone-resistant prostate cancer previously exposed to chemotherapy... - Adjuvant epirubicin with or without Ifosfamide for adult soft-tissue sarcomaRoberto Petrioli
Institute of Internal Medicine, Medical Oncology Division, University of Siena, Policlinico Le Scotte, Viale Bracci, 11, 53100, Siena, Italy
Am J Clin Oncol 25:468-73. 2002..06). The power of the study was 0.65 for both the DFI and overall survival. The results of the study suggest a possible advantage of epirubicin-based adjuvant chemotherapy in patients with soft-tissue sarcoma at high risk of relapse... - Immunotherapy of renal cell carcinoma with granulocyte macrophage colony stimulating factor and very low dose interleukin-2Pierpaolo Correale
Interdipartimental Oncopharmacology Center, Faculty of Medicine, University of Siena, Viale Bracci 11, 53100 Siena, Italy
Oncol Rep 13:751-6. 2005..Our results suggest that this GM-CSF/hrIL-2 combination is active and well tolerated in patients with renal cell carcinoma and deserves to be investigated in larger comparative trials... - Pharmacokinetics of intraarterial mitomycin C in hypoxic hepatic infusion with embolization in the treatment of liver metastasesDaniela Cerretani
Department of Pharmacology G. Segre, University of Siena, Via delle Scotte 6, 53100 Siena, Italy
Vascul Pharmacol 39:1-6. 2002..001). 4. The reduction in AUC following HHMI explains the limited systemic toxicity in treated patients, with a greater total tumor exposure to the drug and improved drug activation... - Folinic acid, 5-fluorouracil and etoposide after curative resection for gastric cancerRoberto Petrioli
Department of Medical Oncology, University of Siena, Italy
Hepatogastroenterology 52:1626-30. 2005..CONCLUSIONS: Our data suggest that ELF adjuvant treatment is a safe and well tolerable combination chemotherapy in patients with resected gastric cancer, but it does not seem to improve prognosis in comparison with historical controls... - Chemotherapy regimen GOLF induces apoptosis in colon cancer cells through multi-chaperone complex inactivation and increased Raf-1 ubiquitin-dependent degradationMichele Caraglia
Experimental Oncology Department, National Cancer Institute Fondazione G Pascale, Naples, Italy
Cancer Biol Ther 4:1159-67. 2005..These effects likely occurred through the disruption of critical survival pathways and the inactivation of multi-chaperone complex... - Treatment of colon and breast carcinoma cells with 5-fluorouracil enhances expression of carcinoembryonic antigen and susceptibility to HLA-A(*)02.01 restricted, CEA-peptide-specific cytotoxic T cells in vitroPierpaolo Correale
Oncopharmacology Center, School of Medicine, University of Siena, Italy
Int J Cancer 104:437-45. 2003..These results provide a rationale for investigating a possible new role of 5-FU as an immuno targeting amplifier agent in breast and colorectal cancer patients immunized with CEA-directed cancer vaccines... - Chemo-immunotherapy of colorectal carcinoma: preclinical rationale and clinical experiencePierpaolo Correale
Center of Oncopharmacological Research, Faculty of Medicine, University of Siena, Italy
Invest New Drugs 24:99-110. 2006..This report tries to review the possible rationale of the chemo-immunotherapy combination, illustrating preliminary results of preclinical and clinical studies... - A polyepitope DNA vaccine targeted to Her-2/ErbB-2 elicits a broad range of human and murine CTL effectors to protect against tumor challengeAntonio Scardino
Institut National de la Santé et de la Recherche Médicale U753, Institut Gustave Roussy, Villejuif, France
Cancer Res 67:7028-36. 2007..These data indicate that the pVax1/pet-neu cDNA vaccine coding for a poly-ErbB-2 epitope is able to generate simultaneous ErbB-2-specific antitumor responses against dominant and cryptic multiple epitopes...